Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Gastrointestinal Stromal Tumor
100%
Malignant Neoplasm
71%
Ovarian Cancer
63%
Neoplasm
61%
Symptomatic Treatment
58%
Overall Survival
35%
Imatinib
31%
Krukenberg Tumor
28%
Bone Metastasis
25%
Quality of Life
24%
Progression Free Survival
24%
Disease
24%
Symptom
22%
Systemic Therapy
21%
Basal-Cell Carcinoma
21%
Targeted Therapy
20%
Bevacizumab
19%
Clinician
18%
Oncology
17%
Cervical Cancer
17%
Breast Cancer
17%
Metastatic Carcinoma
16%
Radiation Therapy
15%
Advance Care Planning
15%
Positron Emission Tomography
14%
Exon
14%
Medical Oncology
13%
Patient Referral
12%
Vasculotropin A
12%
Chemoradiotherapy
12%
Cancer Research
12%
Cordotomy
12%
Adverse Event
12%
Health Care
12%
Positron Emission Tomography
11%
Arm
11%
Advanced Cancer
11%
Clinical Trial
11%
Intensive Care Unit
11%
Nodular Melanoma
10%
Receptor Expression
10%
Randomized Controlled Trial
10%
Anticarcinogen
10%
Biological Marker
10%
Neoadjuvant Chemotherapy
10%
Circulating Tumor DNA
10%
Hormone Receptor
9%
Progressive Disease
9%
Immunotherapy
9%
Hospital Care
9%
Pharmacology, Toxicology and Pharmaceutical Science
Gastrointestinal Stromal Tumor
92%
Imatinib
58%
Malignant Neoplasm
48%
Ovary Cancer
43%
Chemotherapy
41%
Neoplasm
33%
Sunitinib
32%
Overall Survival
29%
Progression Free Survival
27%
Ovary Carcinoma
26%
Carboplatin
21%
Vasculotropin A
19%
Protein Tyrosine Kinase Inhibitor
18%
Disease
17%
Cohort Study
17%
Chemoradiation Therapy
17%
Bevacizumab
16%
Adverse Event
16%
Pharmacokinetics
16%
Therapeutic Drug Monitoring
14%
Biological Marker
14%
Vasculotropin
13%
Uterine Cervix Cancer
13%
Prospective Study
13%
Soft Tissue Sarcoma
12%
Side Effect
12%
Trabectedin
12%
Protein P53
12%
Paclitaxel
12%
Melanoma
11%
Clinical Trial
11%
Anticarcinogen
11%
Prevalence
11%
Cyclophosphamide
10%
Everolimus
9%
Symptom
8%
Peptide Vaccine
8%
Metformin
8%
Oxycodone
8%
Endothelial Nitric Oxide Synthase
8%
Hormone Receptor
8%
Doxorubicin
8%
Placebo
8%
Immune Checkpoint Inhibitor
8%
Receptor
7%
Life Expectancy
7%
Immunotherapy
7%
Comorbidity
6%
Monotherapy
6%
Disease Exacerbation
6%
Keyphrases
Gastrointestinal Stromal Tumor
45%
Dutch
39%
Netherlands
21%
Ovarian Cancer
19%
Tumor Patients
17%
Radiotherapy
17%
Imatinib
17%
Palliative Care
12%
Sunitinib
12%
Painful Bone Metastasis
12%
Therapeutic Drug Monitoring
12%
Incurable Cancer
12%
Neoadjuvant
11%
Treatment Options
11%
Oncology
11%
Tumor Registry
10%
Advance Care Planning
10%
Progression-free Survival
10%
Quality of Life
9%
Older Patients
9%
Overall Survival
9%
Metastatic Gastrointestinal Stromal Tumor
9%
Clinical Outcomes
9%
In Cancer
9%
Cancer Patients
9%
Systemic Therapy
8%
Dose Reduction
8%
Phase II Study
8%
Treatment Goals
8%
Metallic Taste
8%
Neoadjuvant Chemotherapy
8%
Registry Data
8%
Prioritization Tool
8%
Retrospective Record Review
8%
Endometrial Cancer
8%
Phase I Study
8%
Integrated Palliative Care
8%
Delphi Study
8%
Advanced Gastrointestinal Stromal Tumor
7%
Systemic Treatment
6%
Patients with Advanced Cancer
6%
Survivors
6%
Adverse Events
6%
Patient Management
5%
Pembrolizumab
5%
Progressive Disease
5%
Oncology Care
5%
Pharmacology
5%
Health Care Use
5%
Randomized Controlled Trial
5%